Grants for For profit organizations other than small businesses - Science and Technology

In FY23, the OCRP established a new academy, the Ovarian Cancer Clinical Trial Academy (OCCTA), which will focus on clinical trial research in ovarian cancer. The intent of the OCCTA is to enhance knowledge within next generation of Early-Career Investigators (ECIs) in clinical trial research and to produce effective treatments and cures for ovarian cancer. The OCCTA will bring together established investigators (the Academy Dean and Assistant Dean), established Career Guides (mentors), and a group of ECIs/Scholars to conduct successful, highly productive clinical trials in ovarian cancer. The OCCTA strives to develop successful, highly productive ovarian cancer clinical trialists in a collaborative research and career development environment, providing intensive mentoring, national networking, collaborations, and a peer group for junior clinical trialists. The OCCTA, through its Leadership, provides for professional and leadership development of the ECIs to include skills and competencies needed to execute clinical trials.

This grant provides $5,000 to nonprofit organizations in Southern California that support underserved Asian and Pacific Islander communities by enhancing their workforce capacity and operational stability.

This funding opportunity supports researchers in atmospheric science to utilize satellite data for advancing the understanding of precipitation, cloud dynamics, and related processes, particularly through the integration of legacy and current satellite missions.

This grant provides funding for full-time graduate students in the Western U.S. to collaborate with their academic advisors and local producers on projects that promote sustainable agriculture through research and education.

This funding opportunity provides financial support for research projects that enhance data collection and analysis related to breast cancer, specifically targeting gaps in existing clinical studies and involving consumer advocates in the research process.

Grant Opportunity: Grand Strategy Research Grants Funder: Charles Koch Foundation The Grand Strategy Research Grants program, funded by the Charles Koch Foundation, aims to support scholars and research institutions interested in challenging the current approach to U.S. foreign policy and providing alternative visions. The program is open to proposals from various fields, with a particular interest in political science, international relations, history, and economics. The grant opportunity seeks research projects that explore topics such as a grand strategy of restraint, the role of values and ethics in U.S. foreign policy formulation, unintended consequences of military actions abroad, impact on American society and civil liberties, executive-legislative relations in foreign policy, influence of interest groups on foreign policy decisions, growth of intelligence and national security establishments since 9/11, costs and impacts of foreign aid and alliance commitments, Pentagon spending and defense policy demands, consequences of a multipolar world, and leveraging technology for a sound approach to grand strategy. Applicants are required to submit a two-to-five page abstract of the project along with a CV or résumé and a brief itemized budget. Final projects should be original and meet high standards in their respective fields. Funding levels will depend on the research requirements and potential for advancing understanding of critical issues. Accepted proposals may also receive support for disseminating research findings. Proposals will be accepted on a rolling basis. Interested applicants can find more information about the grant opportunity and access the application form on the Charles Koch Foundation's website at https://charleskochfoundation.tfaforms.net/344037?tfa_13=tfa_22

This ISO seeks solution summaries and proposals for projects that fall within the general scope of the ARPA-H Scalable Solutions mission office. SSO expands what is technically possible by developing approaches that will leverage an interdisciplinary approach and collaborative networks to address challenges of geography, distribution, manufacturing, data and information, thereby improving health care access and affordability. In the United States, many communities and remote areas lack access to timely and quality health care, which leads to disparities in health outcomes for those populations. Bottlenecks during the manufacturing processes of products and health technologies also lead to delays and limited availability, preventing effective distribution of health care solutions to areas of need, especially in emergencies.ARPA-H SSO seeks solutions to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise by developing location-specific interventions, telemedicine solutions, and mobile health clinics. Solutions should focus on rapid innovation and the use of partnerships, as well as flexible distribution networks and streamlined manufacturing processes. The following SSO interest areas categorize the ground-breaking solutions we seek to support:Scalable Technologies and Interventions: Approaches to improve affordability and equitable access to health care that are adaptable to various geographic, demographic, economic contexts and can be rapidly deployed at scale (e.g., drug-repurposing*, telemedicine, point-of-care diagnostics, and modular health care infrastructure). Tailored solutions for the pediatric population that provide parity in access to treatments and other health care interventions with the adult population and adapt to the pediatric patients changing physiology and developmental status over the course of years. Transformational approaches to reduce or eliminate health disparities, including tools and models for product design and care delivery that scale novel approaches in human factors and human-centered design to respond to full diversity of patients. Tools to enable the scaling of provider and institutional capabilities (e.g., school nurses and schools, walk-in clinics, homesteading care) to address unmet health care access needs and expand availability of critical services. Foundational capabilities to accelerate diagnoses and reduce the cost of treatments for rare diseases wherever patients are, without the need for specialized facilities or healthcare expertise.* Solution summaries and proposals that focus on testing drugs for effectiveness for other disease states or use cases, are unlikely to be funded unless including additional R, or providing gains in cost reduction, accessibility, and/or equity.Collaborative Distribution Networks: Methods for standardization, automation, and democratization of complex procedures 5 including, but not limited to, histopathology, rare disease diagnosis and treatment, and surgical interventions to ensure access and delivery to populations diverse in demographics, geographies, and resources at scale. Approaches to enhance delivery of effective healthcare solutions in rural or low resource settings, including but not limited to "last mile delivery, at-home monitoring, imaging, drug delivery, telehealth augmentation, and support for remote medical procedures with limited need for specialized training. Technologies to enable the deployment of critical healthcare resources rapidly, equitably, and securely at scale to the point of need in permissive and non-permissive (i.e., damaged infrastructure, cyber-denied) environments during a public health crisis or natural disaster. Solutions to scale education and training of critical healthcare resources for health care providers and patients to ensure information integrity to prevent negative impacts to resource use/uptake. Innovative information technology, data and analytic products and technologies to enable ordering, inventory management, situational awareness, allocation planning and demand forecasting of critical healthcare resources during a public health crisis or natural disaster.Biomanufacturing Innovations*: Innovative manufacturing technologies and approaches that reduce cost, shorten the timeline for production, advance domestic competitiveness and reduce supply chain risk of biologics, cellular and gene therapies, pharmaceuticals, medical devices and personal protective equipment. New approaches to support predictable, programable biological production of conventional and novel materials reliability at scale in a cost-effective sustainable manner. Novel solutions to reduce the reliance on specialized handling and cold chain management of pharmaceuticals and biologics. Scalable innovations to advance and strengthen biomanufacturing supply chain and resolve bottlenecks including:o Advances in production of active pharmaceutical ingredients, process consumables, and other critical materials (i.e., enzymes, cell lines, etc);o Novel biomanufacturing-related data products, technologies or models to integrate into supply chain situational awareness systems;o Alternative materials and new manufacturing capabilities for personal protective equipment; ando Improvement of capabilities sustainably re-shore manufacturing and utilize a broad array of readily accessible and cost-efficient feedstocks as part of strengthening the local and national industry base. Analytics and novel sensor systems to precisely manage bioproduction, real-time release assays, and predictive capabilities to inform tuning of biological chassis for efficient and effective scale-up of manufacturing to industrial scale.*ARPA-H is not interested in approaches that merely increase capacity reservation.Other high-quality submissions that propose revolutionary technologies that meet the goals of SSO will be considered even if they do not address the topics listed above.Proposals are expected to use innovative approaches to enable revolutionary advances in medicine and healthcare, and the science and technology underlying these areas. While approaches that are disease agnostic are encouraged, ARPA-H welcomes proposals that bring radically new insights to address specific diseases including, but not limited to, cancer, diabetes, neurological diseases, pediatric and maternal/fetal health, infectious diseases, and cardiovascular disease.Specifically excluded are proposals that represent an evolutionary or incremental advance in the current state of the art or technology that has reached the clinical trial stage. An example of this type of proposal might include the request to fund clinical trials of an otherwise developed product. Additionally, proposals directed towards policy changes, traditional education and training, or center coordination, formation, or development, and construction of physical infrastructure are outside the scope of the ARPA-H mission.

This funding opportunity supports cities, counties, and organizations in Iowa to implement urban conservation projects that reduce nutrient pollution and improve water quality through stormwater management and community education.

The GEL-ICS program will build a cohesive group of leaders working on issues in cyberspace who are committed to the UN-affirmed Framework of Responsible State Behavior and will be equipped with the necessary knowledge and global connections to be effective advocates and champions of the Framework through the fellowship and other activities.

This funding opportunity supports early-career researchers in ovarian cancer clinical trials by providing financial resources, mentorship, and professional development through a specialized academy.

The City of Boulder Health Equity Fund (HEF) Request for Proposals (RFP) is designed to support community-based health equity programs for Boulder residents experiencing health disparities. The fund aims to reduce systemic socio-economic and health barriers, aligning with the city's mission to achieve health equity—defined as the absence of systematic health disparities and the ability of all residents to reach their full health potential regardless of life circumstances. This initiative directly supports health and wellness programs that address these disparities. The target beneficiaries of the HEF include residents disproportionately impacted by diseases linked to sugar-sweetened beverage consumption or targeted by SSB marketing, those lacking access to healthy food, safe water, quality health care, wellness information, and health care services, and populations systemically disenfranchised due to race, ethnicity, income, age, ability, sexual orientation, or gender identification. The primary impact goal is to improve health equity and reduce health disparities within these vulnerable communities. The HEF prioritizes programs that benefit individuals most affected by or at increased risk from chronic diseases linked to sugary drink consumption, or who generally experience health disparities. Key focuses include health services for prevention of obesity, diabetes, heart disease, and oral diseases, increased access to healthy food and clean water, wellness programs, and physical fitness. The program also emphasizes leadership diversity reflective of client demographics, alignment with program priorities, evidence-based practices, and valuing lived experience and cultural knowledge. Expected outcomes and measurable results include long-term evaluation of outcomes, meaningful engagement of community members in program design and implementation, strong collaborations, cost-effectiveness, and demonstrated financial stability and diverse funding sources for applying agencies. The City of Boulder's strategic priority is to fund programs that directly address health inequities and contribute to a community where all residents can achieve their full health potential. The underlying theory of change is that by investing in targeted, community-based health and wellness programs, the city can systematically dismantle health barriers and create a more equitable health landscape for its residents.

This funding opportunity provides financial support for U.S.-based organizations to conduct research on innovative construction technologies and policies that can help increase the availability of affordable housing nationwide.

This funding opportunity is designed for non-U.S.-based research entities to develop innovative AI technologies that improve maritime security through enhanced scene perception for unmanned vessels in complex marine environments.

The Water Resources Preservation Grant Program, funded by the Upper Guadalupe River Authority (UGRA), provides cost-share funding to support the design and construction of stormwater management practices. These practices, referred to as Best Management Practices (BMPs), include Low Impact Development (LID), nature-based solutions, and Green Stormwater Infrastructure (GSI). The goal is to reduce, infiltrate, filter, and delay stormwater runoff, thus protecting the health of waterways in Kerr County. Eligible projects can apply for rebates that cover a portion of the costs associated with these practices, with the aim of reducing pollutants like Total Suspended Solids (TSS) and Bacteria by significant percentages. The program supports new constructions or retrofits, emphasizes distributed and centralized treatment methods, and requires adherence to specific design guidelines.

This grant provides funding and opportunities for companies and coalitions developing innovative energy storage solutions that enhance the integration of renewable energy systems and improve the efficiency of the electricity grid.

This program provides funding to early-career scientists and engineers in the U.S. to support innovative research that aligns with the missions of the Air Force and Space Force.

Please note that this program requests optional Notices of Intent, which are due via NSPIRES by July 15, 2024. See the full posting on NSPIRES for details. Proposers must retrieve the instructions document (zip file) associated with the application package for this opportunity as there is at least one required form that must be attached to the submitted proposal package. The National Aeronautics and Space Administration (NASA) Science Mission Directorate (SMD) released its annual omnibus Research Announcement (NRA), Research Opportunities in Space and Earth Sciences (ROSES) 2024 (OMB Approval Number 2700-0092, CFDA Number 43.001) on February 14, 2024. In this case "omnibus" means that this NRA has many individual program elements, each with its own due dates and topics. All together these cover the wide range of basic and applied supporting research and technology in space and Earth sciences supported by SMD. Awards will be made as grants, cooperative agreements, contracts, and inter- or intra-agency transfers, depending on the nature of the work proposed, the proposing organization, and/or program requirements. However, most extramural research awards deriving from ROSES will be grants, and many program elements of ROSES specifically exclude contracts, because contracts would not be appropriate for the nature of the work solicited. The typical period of performance for an award is three years, but some programs may allow up to five years and others specify shorter periods. In most cases, organizations of every type, Government and private, for profit and not-for-profit, domestic and foreign (with some caveats), may submit proposals without restriction on teaming arrangements. Tables listing the program elements and due dates (Tables 2 and 3), a table that provides a very top level summary of proposal contents (Table 1), and the full text of the ROSES-2024 "Summary of Solicitation", may all be found NSPIRES at http://solicitation.nasaprs.com/ROSES2024. This synopsis is associated with one of the individual program elements within ROSES, but this is a generic summary that is posted for all ROSES elements. For specific information on this particular program element download and read the PDF of the text of this program element by going to Tables 2 or 3 of this NRA at http://solicitation.nasaprs.com/ROSES2024table2 and http://solicitation.nasaprs.com/ROSES2024table3, respectively, click the title of the program element of interest, a hypertext link will take you to a page for that particular program element. On that page, on the right side under "Announcement Documents" the link on the bottom will be to the PDF of the text of the call for proposals. For example, if one were interested in The Lunar Data Analysis Program (NNH24ZDA001N-LDAP) one would follow the link to the NSPIRES page for that program element and then to read the text of the call one would click on C.8 Lunar Data Analysis Program (.pdf) to download the text of the call. If one wanted to set it into the context of the goals, objectives and know the default rules for all elements within Appendix C, the planetary science division, one might download and read C.1 Planetary Science Research Program Overview (.pdf) from that same page. While the letters and numbers are different for each element within ROSES (A.12, B.7, etc.) the basic configuration is always the same, e.g., the letter indicates the Science Division (A is Earth Science, B is Heliophysics etc.) and whatever the letter, #1 is always the division overview. Frequently asked questions for ROSES are posted at http://science.nasa.gov/researchers/sara/faqs. Questions concerning general ROSES-2024 policies and procedures may be directed to Max Bernstein, Lead for Research, Science Mission Directorate, at [email protected], but technical questions concerning specific program elements should be directed to the point(s) of contact for that particular element, who may be found either at the end of the individual program element in the summary table of key information or on the web list of topics and points of contact at: http://science.nasa.gov/researchers/sara/program-officers-list. Not all program elements are known at the time of the release of ROSES. To be informed of new program elements or amendments to this NRA, proposers may subscribe to: (1) The SMD mailing lists (by logging in at http://nspires.nasaprs.com and checking the appropriate boxes under "Account Management" and "Email Subscriptions"), (2) The ROSES-2024 blog feed for amendments, clarifications, and corrections to at https://science.nasa.gov/researchers/solicitations/roses-2024/, and (3) The ROSES-2024 due date Google calendars (one for each science division). Instructions are at https://science.nasa.gov/researchers/sara/library-and-useful-links (link from the words due date calendar).

The Seminole County is currently accepting grant applications for the Home-ARP Program, a critical initiative designed to mitigate homelessness and enhance housing stability for qualifying populations within the county. This program is a direct outgrowth of the HOME-American Rescue Plan (HOME-ARP), which saw Congress allocate $5 billion as part of the broader $1.9 trillion COVID-19 pandemic relief efforts on March 11, 2021. The Department of Housing and Urban Development (HUD) administers these funds, with Seminole County having received $3,046,438. This funding was officially approved by the Board of County Commissioners on March 14, 2023, and subsequently by HUD, underscoring its alignment with federal strategies to address housing insecurity exacerbated by the pandemic. The primary target beneficiaries of the Home-ARP Program are individuals and families experiencing or at risk of homelessness, as well as other qualifying populations as defined by HUD. The program's overarching impact goal is to significantly reduce homelessness and increase housing stability across Seminole County. This will be achieved through a multi-faceted approach, including the development of affordable rental housing, provision of supportive services, and capacity building for non-profit organizations. By focusing on these areas, the program aims to create a more resilient and equitable housing landscape for vulnerable residents. The program's priorities and focuses are clearly outlined through its funding allocation. A substantial portion, $2,137,151, is dedicated to the development of affordable rental housing, highlighting a strategic emphasis on increasing the supply of safe and accessible housing units. Additionally, $300,000 is allocated for supportive services, recognizing that stable housing often requires concurrent support for health, employment, and other social needs. Furthermore, $152,321 is earmarked for Non-Profit Capacity Building/Operating Costs, demonstrating an understanding that strong, well-resourced community partners are essential for effective program implementation. Finally, $456,966 is allocated for administration and planning, ensuring efficient oversight and strategic deployment of resources. Expected outcomes include a measurable reduction in the number of individuals experiencing homelessness in Seminole County, an increase in the availability of affordable rental housing units, and improved access to essential supportive services for at-risk populations. The program anticipates strengthening the capacity of local non-profit and for-profit organizations to address community development and housing needs. These outcomes will be achieved through projects implemented either directly by the County or in partnership with qualified non-profit agencies or for-profit organizations, aligning with a theory of change that posits collaborative efforts and strategic investment in housing and support services will lead to enhanced housing stability and a decrease in homelessness.

The FY24 BCRP Clinical Research Extension Award aims to extend or expand the data collection, follow-up, and analysis of breast cancer clinical studies. The intent of this mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. Patients contributions of tissue, serum, and other biologic specimens and their data are invaluable to saving lives. The BCRP has created this mechanism to help ensure that science values those contributions with research that maximizes their impact.The critical components of this award mechanism are:Impact: Research supported by the FY24 BCRP Clinical Research Extension Award will have the potential to extend or affect the impact of the previously funded clinical trial or study or will result in new impact and accelerate progress toward ending breast cancer.Research Scope: Although not all-inclusive, research proposed under the FY24 BCRP Clinical Research Extension Award may entail a deeper molecular analysis of clinical samples, initiation of new correlative studies, biomarker validation, or continuing clinical follow-up of patients enrolled in an open/ongoing or completed clinical trial. The proposed research may be hypothesis-testing or -generating or may be designed to generate clinically annotated and molecularly characterized experimental platforms, including patient-derived models or tissue arrays. Innovation is not a criterion for this award mechanism. Projects proposing to conduct clinical trials will not be supported.Feasibility: Preliminary data to support the scientific rationale and feasibility of the research approaches are required. The applicant must demonstrate availability of, and accessibility to, the necessary resources or populations to accomplish the proposed research.Data Evaluation and Sharing: Proposed research should be based on a study sample size that will ensure that the results support valid conclusions or will generate a meaningful hypothesis. It is the applicants responsibility to provide sufficient evidence that the sample size is appropriate to meet the studys objectives and outline the statistical methods and considerations they will employ in their data analysis. The applicant must outline a data-sharing plan for the scientific community to have access to the experimental platforms and molecular and other data generated from the proposed research.applications that include meaningful and productive partnerships between investigators. The Partnering PI Option is structured to accommodate two Principal Investigators (PIs). One PI will be identified as the Initiating PI, who will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring a distinct contribution to the application. Both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. The application should clearly demonstrate that both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project. It is expected that funding will be balanced between both PIs unless appropriately justified. The application is expected to describe how the PIs unique expertise combined as a partnership will better address the research question, how the unique expertise that each individual brings to the application is critical for the research strategy and completion of the SOW, and why the work should be done together rather than through separate efforts. Applicants are discouraged from being named as a PI, Initiating PI, or Partnering PI on multiple Clinical Research Extension Award applications unless they are clearly addressing distinct research questions. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PIs, refer to Section II.D.2, Content and Form of the Application Submission.Personnel: Applications are expected to include an appropriate and robust research team with the combined backgrounds and breast cancer-related expertise to enable successful conduct of the project.Consumer Advocates: Applications are required to include consumer advocate involvement. The research team must include two or more breast cancer consumer advocates, and it is the applicants responsibility to outline the advocates role in the design and execution of the study. As lay representatives, the consumer advocates must be individuals who have been diagnosed with breast cancer and are actively involved in a breast cancer advocacy organization. Their role should be independent of their employment, and they may not be employees of any organizations participating in the application. The consumer advocates should have a high level of knowledge of current breast cancer issues and the appropriate background and/or training in breast cancer research to contribute to the project. Their role should be focused on providing objective input throughout the research effort and its potential impact for individuals with, or at risk for, breast cancer.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 BCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military Families, and the American public.Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects that may or may not be considered a clinical trial. For this funding opportunity, research involving human subjects, human specimens, and data, including extended or expanded clinical follow-up of patients, is permitted; however, this award cannot be used to conduct clinical trials.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP Clinical Research Extension Award should not exceed $5M for applications with a single PI or $6M if applying under the Partnering PI Option. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $18.6M to fund approximately two Clinical Research Extension Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The California Department of Food and Agriculture is offering a grant of over $1 million through its Dairy Plus Program to California dairy farms for implementing advanced manure management practices that reduce methane emissions and manage nitrogen and salt surplus, with a focus on climate-smart practices and product markets.